{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-139094","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.069104+00:00","generated_at":"2026-05-15T07:52:11.563754+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics founder Howard Berman steps down as Executive Chairman; Mark Pavao appointed independent director","bullets":["Howard Berman resigned as Executive Chairman and Board member effective April 1, 2026; part of planned CEO transition initiated November 2024.","Separation agreement includes prorated 2026 bonus at 100% target, COBRA coverage through March 2027, and continued vesting of stock options for 12 months.","Mark H. Pavao appointed as independent Class III director, term expiring at 2028 annual meeting; granted option for 10,000 shares vesting in one year.","Pavao brings 30+ years of biopharma commercial experience, including roles at Bristol-Myers Squibb and R-Pharm US."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-139094","json":"https://secwatch.observer/filing/0001193125-26-139094.json","markdown":"https://secwatch.observer/filing/0001193125-26-139094.md","text":"https://secwatch.observer/filing/0001193125-26-139094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526139094/0001193125-26-139094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526139094/d104763d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:52:11.563754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}